Zanolimumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameZanolimumab
Drug Alias Name扎木单抗Anti-CD4 monoclonal antibody MDX CD4Zanolimumabum扎利木单抗Anti-CD4 monoclonal antibody HuMax-CD4 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CD4Viral fusion proteins inhibitors
TargetsT-cell surface antigen CD4Viral fusion proteins
Therapy Area/IndicationsArthritis, RheumatoidKidney NeoplasmsMelanoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmergent Product Development Seattle LlcGenmab A/SEmergent Biosolutions Inc +[4] 
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidKidney NeoplasmsMelanoma +[7] 

Other Information

ATC CodeN/A
Related LinksN/A